GT Biopharma
GTBP • NASDAQ
GT Biopharma is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Michael Martin Breen, with a market cap of $12.9M.
CEOMichael Martin Breen
Next Earnings
Upcoming earnings announcement for GT Biopharma
Date
Thursday, May 14, 2026 (in a month)
Timing
Time TBD (3:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.08
Earnings History
Past 12 earnings reports for GT Biopharma
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 2, 2026 | Q4 2025 | -$4.84 | — | - | — |  10-K |
| Nov 14, 2025 | Q3 2025 | -$0.83Est: -$0.31 | -167.7% | - | — | 10-Q |
| Aug 14, 2025 | Q2 2025 | -$0.55Est: -$0.68 | +19.1% | - | — | 10-Q |
| May 15, 2025 | Q1 2025 | -$0.33 | — | - | — | 10-Q |
| Feb 21, 2025 | Q4 2024 | -$1.66 | — | - | — | 10-K/A |
| Nov 14, 2024 | Q3 2024 | -$1.53 | — | - | — | 10-Q |
| Aug 14, 2024 | Q2 2024 | -$2.17 | — | - | — | 10-Q |
| May 15, 2024 | Q1 2024 | -$1.64Est: -$2.70 | +39.3% | - | — | — |
| Mar 26, 2024 | Q4 2023 | -$2.14Est: -$2.70 | +20.7% | - | — | — |
| Nov 1, 2023 | Q3 2023 | -$1.80Est: -$3.00 | +40.0% | - | — | — |
| Aug 7, 2023 | Q2 2023 | -$1.50Est: -$3.00 | +50.0% | - | — | — |
| May 15, 2023 | Q1 2023 | -$0.30Est: -$4.20 | +92.9% | - | — | — |